Table 2 Factors associated with mortality in Sch-PAH patients.

From: Clinical and hemodynamic evaluation of schistosomiasis-associated pulmonary arterial hypertension from Egyptian pulmonary hypertension centers: epidemiology, risk factors, and survival determinants

Factors

Death (n = 7)

Survival (n = 34)

P

Mean/ N

SD/ %

Mean/ N

SD/ %

Age

49.1

15

50.7

11.6

0.81†

Male

3

42.86

25

73.53

0.18*

Comorbidity

1

14.29

10

29.41

0.41*

FC/NYHA

I/II

4

57.14

14

41.18

0.44*

III/IV

3

42.86

20

58.82

 

6MWD(m)

262.9

43.1

303.5

87.1

0.08†

Echo

PASP(mmHg)

81.3

30.9

86.1

23

0.73†

RA

6

85.71

33

97.06

0.31*

RV

6

85.71

33

97.06

0.31*

LA

2

28.57

16

47.06

0.36*

Pericardial effusion

1

14.29

3

8.82

0.54*

EF %

72.67

5.5

64.96

5.33

0.01†

Heamodynamics

mRAP

12.5

6.06

9.39

5.94

0.29†

mPAP

55.5

12.8

54.8

11.8

0.91†

CI

2.265

0.885

2.57

1.09

0.48†

PVR

13.11

7.94

11.67

5.68

0.68†

Svo2

54.17

8.89

61.88

8.3

0.09†

PA dilatation

3

42.86

3

8.82

0.02*

PoHT

4

57.14

6

17.65

0.02

Treatment

Selected medication

6

85.71

31

91.18

0.54*

Mono-Therapy

0

0

5

14.71

0.56*

Combination Therapy

6

85.71

26

76.47

0.59*

Diuretics

3

42.86

25

73.53

0.11*

  1. Continuous data represented as mean and stander deviation (SD), and categorical data as number and percentage (%). N, number; SD, stander deviation; †: Independent t-test, *: Chi square test, P < 0.05 is statistically significant
  2. FC, Functional class; NYHA, New York Heart Association; PA, Pulmonary artery; RA, right atrium; RV, right ventricle; LA, left atrium; EF, ejection fraction; 6MWD, 6 min’ walk distance.
  3. mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; CI, cardiac index; PVR, pulmonary vascular resistance; SVo2, oxygen saturation in the mixed venous blood.
  4. CT, computed tomography; PoHT, Porto Pulmonary hypertension.
Back to article page